BMY vs HBAN · P/E 17, rev $24.46B vs P/E 13, rev $1.56B
Bristol-Myers Squibb Company (BMY) versus Huntington Bancshares Incorporated (HBAN) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Christopher S. Boerner Ph.D..
Huntington Bancshares Incorporated (HBAN) is a banks - regional company listed on US.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported HBAN revenue for 2025-12-31 was $1.56B. Net income was $2.21B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
Not investment advice. Open the BMY and HBAN stock pages for the full models.
Not investment advice.